Mechanisms of dexamethasone-induced bone toxicity in developing bone: a single-cell perspective
Authors:
- Kelly WarminkKWKelly Warmink
- Philip LijnzaadPLPhilip Lijnzaad
- Stephanie A SchubertSSStephanie A Schubert
- Tristan W VermaatTVTristan W Vermaat
- Lisa JansenLJLisa Jansen
- Marloes C van GendMGMarloes C van Gend
- Marieke van de VenMVMarieke van de Ven
- Johannes H M MerksJMJohannes H M Merks
- Thanasis MargaritisTMThanasis Margaritis
Open Access
- 8 September 2025
- journal article
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 9 (10)
Abstract
Glucocorticoids, such as dexamethasone, are essential for treating severe childhood conditions, including cancer, organ transplantation, and inflammatory disorders. However, their long-term use can impair bone development, posing risks to pediatric bone health, which is vital for lifelong skeletal integrity. A mechanistic insight into how glucocorticoids negatively impact bone could improve decision-making in patient care, thereby improving the quality of life for pediatric cancer patients and survivors. In this study, we aimed to elucidate the molecular mechanisms underlying dexamethasone-induced bone toxicity in developing bones using single-cell transcriptomics. We treated skeletally immature C57BL/6JRj male mice with dexamethasone for 28 d, and assessed the bone architecture with micro-computed tomography, and characterized bone and bone marrow cells from the femurs using single-cell RNA sequencing. Our findings revealed a marked reduction in osteoblast and chondrocyte cell populations and impaired function of pre-osteoblasts. Additionally, dexamethasone adversely affected B cell subsets, significantly depleting early B cell progenitors while allowing some further developed immature B cells to persist. These cellular changes were accompanied by reduced longitudinal bone growth, compromised bone architecture, and increased bone fragility at the highest doses of dexamethasone. Interestingly, unlike observations in adults, dexamethasone did not enhance osteoclast activity in our model. Overall, our study suggests that the adverse effects of dexamethasone on bone development are primarily due to its impact on osteoblastic, chondroblastic and B cell lineages, disrupting the critical signaling crosstalk between the cells necessary for bone development and hematopoiesis.Keywords
All Related Versions
This publication has 49 references indexed in Scilit:
- Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: A longitudinal study of gene expression in bone tissue from glucocorticoid‐treated miceArthritis & Rheumatism, 2008
- Osteoporosis in children with cancerPediatric Blood & Cancer, 2007
- Bisphosphonate therapy for children and adolescents with secondary osteoporosisCochrane Database of Systematic Reviews, 2007
- Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cellsBone, 2006
- Early lymphoid progenitors in mouse and man are highly sensitive to glucocorticoidsInternational Immunology, 2005
- Glucocorticoids Act Directly on Osteoblasts and Osteocytes to Induce Their Apoptosis and Reduce Bone Formation and StrengthEndocrinology, 2004
- Osteocyte viability with glucocorticoid treatment: relation to histomorphometryAnnals of the Rheumatic Diseases, 2003
- 1,25-Dihydroxyvitamin D-Responsive Element and Glucocorticoid Repression in the Osteocalcin GeneScience, 1989
- Effect of short-term glucocorticoids on serum osteocalcin in healthy young menJournal of Bone and Mineral Research, 1988
- Effect of Glucocorticoids on Type I Collagen Synthesis, Alkaline Phosphatase Activity, and Deoxyribonucleic Acid Content in Cultured Rat Calvariae*Endocrinology, 1983